MXPA05007822A - Combination therapy for treating protein deficiency disorders. - Google Patents
Combination therapy for treating protein deficiency disorders.Info
- Publication number
- MXPA05007822A MXPA05007822A MXPA05007822A MXPA05007822A MXPA05007822A MX PA05007822 A MXPA05007822 A MX PA05007822A MX PA05007822 A MXPA05007822 A MX PA05007822A MX PA05007822 A MXPA05007822 A MX PA05007822A MX PA05007822 A MXPA05007822 A MX PA05007822A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- protein deficiency
- deficiency disorders
- treating protein
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44413603P | 2003-01-31 | 2003-01-31 | |
PCT/US2004/002973 WO2004069190A2 (en) | 2003-01-31 | 2004-02-02 | Combination therapy for treating protein deficiency disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05007822A true MXPA05007822A (en) | 2006-02-10 |
Family
ID=32850826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008215A MX344587B (en) | 2003-01-31 | 2004-02-02 | Combination therapy for treating protein deficiency disorders. |
MXPA05007822A MXPA05007822A (en) | 2003-01-31 | 2004-02-02 | Combination therapy for treating protein deficiency disorders. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008215A MX344587B (en) | 2003-01-31 | 2004-02-02 | Combination therapy for treating protein deficiency disorders. |
Country Status (16)
Country | Link |
---|---|
US (4) | US20040180419A1 (en) |
EP (6) | EP2857036B1 (en) |
JP (5) | JP5589165B2 (en) |
CN (4) | CN102580067A (en) |
BR (1) | BRPI0407001A (en) |
CA (3) | CA2514642C (en) |
CY (5) | CY1116215T1 (en) |
DK (5) | DK1589993T3 (en) |
ES (6) | ES2541952T3 (en) |
HK (4) | HK1158955A1 (en) |
HU (2) | HUE033381T2 (en) |
IL (6) | IL169562A (en) |
MX (2) | MX344587B (en) |
PT (5) | PT1589993E (en) |
SI (5) | SI2857036T1 (en) |
WO (1) | WO2004069190A2 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
SI2857036T1 (en) | 2003-01-31 | 2017-05-31 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
FR2861991B1 (en) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | USE OF GLUCOSIDASE INHIBITORS FOR MUCOVISCIDOSE THERAPY |
US20050256168A1 (en) * | 2004-04-28 | 2005-11-17 | Block Timothy M | Compositions for oral administration for the treatment of interferon-responsive disorders |
EP1896083B1 (en) * | 2005-05-17 | 2016-03-02 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
ES2485369T3 (en) | 2005-06-08 | 2014-08-13 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
DK1986612T3 (en) * | 2006-02-07 | 2012-10-29 | Shire Human Genetic Therapies | Stabilized protein compositions with a free thiol moiety |
PL2787345T3 (en) | 2006-05-16 | 2016-08-31 | Amicus Therapeutics Inc | Treatment options for fabry disease |
MX2009000032A (en) | 2006-06-23 | 2009-01-23 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF beta-GLUCOCEREBROSIDASE. |
WO2008013986A2 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating or preventing ophthalmic light toxicity |
AU2007277033A1 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating or preventing ophthalmic disease |
AU2007277032A1 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Opsin stabilizing compounds and methods of use |
US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
WO2009100037A1 (en) * | 2008-02-01 | 2009-08-13 | The Scripps Research Institute | Methods for treating a condition characterized by dysfunction in protein homeostasis |
WO2010048532A1 (en) * | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
US20100119502A1 (en) * | 2008-11-11 | 2010-05-13 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
CN103432566A (en) | 2008-12-16 | 2013-12-11 | 建新公司 | Oligosaccharide-protein conjugates |
CN106420740A (en) | 2009-02-23 | 2017-02-22 | 伊莫根特病毒学有限责任公司 | Iminosugars and methods of treating viral diseases |
KR101787434B1 (en) * | 2009-02-24 | 2017-11-15 | 유나이티드 세러퓨틱스 코오포레이션 | Iminosugars and methods of treating arenaviral infections |
JP5805630B2 (en) * | 2009-05-26 | 2015-11-04 | アミカス セラピューティックス インコーポレイテッド | Use of pharmacological chaperones to improve biopharmaceutical manufacturing and purification |
US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
WO2010144759A1 (en) | 2009-06-12 | 2010-12-16 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
IN2012DN00352A (en) * | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
CN109172813B (en) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | Compositions and methods for treating gaucher disease |
KR101459530B1 (en) * | 2009-09-04 | 2014-11-07 | 유나이티드 세러퓨틱스 코오포레이션 | Methods of treating poxviral infections |
EP2473046B1 (en) * | 2009-09-04 | 2014-10-22 | United Therapeutics Corporation | Iminosugars for their use in the treatment of filoviral diseases |
PL2473482T3 (en) * | 2009-09-04 | 2014-09-30 | United Therapeutics Corp | Methods of treating orthomyxoviral infections |
WO2011041718A2 (en) * | 2009-10-01 | 2011-04-07 | Baylor Research Institute | Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease |
PL2593131T3 (en) * | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of iduronate-2-sulfatase |
LT3626257T (en) | 2010-06-25 | 2021-12-10 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of arylsulfatase a |
WO2012125402A2 (en) * | 2011-03-11 | 2012-09-20 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
WO2013091897A1 (en) * | 2011-12-22 | 2013-06-27 | Centogene Gmbh | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
CA2865614A1 (en) | 2012-03-02 | 2013-09-06 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type iii gaucher disease |
KR20210062731A (en) | 2012-03-07 | 2021-05-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
US9694056B2 (en) | 2012-07-17 | 2017-07-04 | Amicus Therapeutics, Inc. | α-galactosidase A and 1-deoxygalactonojirimycin co-formulation |
US20160346363A1 (en) * | 2013-07-15 | 2016-12-01 | New York University | Methods and oral formulations for enzyme replacement therapy of human lysosomal and metabolic diseases |
PL3201320T3 (en) | 2014-09-30 | 2024-03-18 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
WO2017117407A1 (en) | 2015-12-30 | 2017-07-06 | Amicus Therapeutics, Inc. | Augmented acid alpha-glucosidase for the treatment of pompe disease |
PT3397273T (en) | 2015-12-30 | 2021-08-09 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
SG11201808455VA (en) | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
PE20190127A1 (en) | 2016-03-30 | 2019-01-17 | Amicus Therapeutics Inc | METHOD FOR SELECTING RECOMBINANT PROTEINS RICH IN M6P |
IL311121A (en) | 2017-03-27 | 2024-04-01 | Regeneron Pharma | Sterilisation method |
JP7066157B2 (en) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | Combinations of drugs for the treatment of Fabry disease and their use |
US11590131B2 (en) | 2017-07-28 | 2023-02-28 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
WO2019084309A1 (en) * | 2017-10-26 | 2019-05-02 | Shire Human Genetic Therapies, Inc. | Formulations comprising glucocerebrosidase and isofagomine |
NL2021840B1 (en) * | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
WO2020046132A1 (en) * | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
CN113906012A (en) * | 2019-04-25 | 2022-01-07 | 武田药品工业有限公司 | Isofagomine salts, methods of use, and formulations |
SG11202111822QA (en) * | 2019-05-07 | 2021-11-29 | Univ Miami | Treatment and detection of inherited neuropathies and associated disorders |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3607858A (en) * | 1970-03-31 | 1971-09-21 | American Cyanamid Co | Process for preparing lyophilized human blood proteins such as gamma globulin in the presence of a nonionic surfactant |
US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US5030638A (en) * | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
US5139749A (en) | 1990-06-22 | 1992-08-18 | Tas, Inc. | Fluidized calcining process |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
AU666118B2 (en) | 1991-04-25 | 1996-02-01 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
AU4115693A (en) * | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5250703A (en) * | 1992-09-29 | 1993-10-05 | Monsanto Company | Pyrrolidin-3,4-diol derivatives of heptitols and preparation thereof |
JP3717925B2 (en) | 1992-09-29 | 2005-11-16 | ネクター セラピューティクス | Pulmonary introduction of active fragments of parathyroid hormone |
US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
ES2204921T3 (en) | 1993-05-27 | 2004-05-01 | Selectide Corporation | SOLID PHASE LIBRARIES CODED, TOPOLOGICALLY SECREGATED. |
FR2718357B1 (en) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Improvements made to a needleless jet injection device. |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US20020013953A1 (en) * | 1995-08-02 | 2002-01-31 | Reuser Arnold J. | Compositions and methods for treating enzyme deficiency |
US20030007963A1 (en) | 1998-12-07 | 2003-01-09 | Van Bree Johannes B. M. M. | Treatment of pompe's disease |
WO1997010817A1 (en) * | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
IL135578A0 (en) * | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
JP2002530059A (en) | 1998-11-13 | 2002-09-17 | サイクラセル・リミテッド | Transport vector |
WO2001007078A1 (en) * | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
US6188045B1 (en) | 2000-04-03 | 2001-02-13 | Alto-Shaam, Inc. | Combination oven with three-stage water atomizer |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020102329A1 (en) * | 2000-07-22 | 2002-08-01 | Michael Lanahan | Methods for high-temperature hydrolysis of galactose-containing oligosaccharides in complex mixtures |
US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
WO2004037373A2 (en) | 2002-10-21 | 2004-05-06 | The Scripps Research Institute | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
SI2857036T1 (en) | 2003-01-31 | 2017-05-31 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
JP2007523648A (en) | 2004-02-06 | 2007-08-23 | バイオマリン ファーマシューティカル インコーポレイテッド | Highly phosphorylated lysosomal enzyme preparations and their use |
EP1896083B1 (en) * | 2005-05-17 | 2016-03-02 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
-
2004
- 2004-02-02 SI SI200432378A patent/SI2857036T1/en unknown
- 2004-02-02 EP EP14197197.8A patent/EP2857036B1/en not_active Expired - Lifetime
- 2004-02-02 EP EP16205400.1A patent/EP3178486B1/en not_active Expired - Lifetime
- 2004-02-02 PT PT04707422T patent/PT1589993E/en unknown
- 2004-02-02 US US10/771,236 patent/US20040180419A1/en not_active Abandoned
- 2004-02-02 SI SI200432253T patent/SI2444102T1/en unknown
- 2004-02-02 MX MX2013008215A patent/MX344587B/en unknown
- 2004-02-02 CN CN2012100331024A patent/CN102580067A/en active Pending
- 2004-02-02 EP EP10011598.9A patent/EP2332567B1/en not_active Expired - Lifetime
- 2004-02-02 EP EP11006504.2A patent/EP2441467B1/en not_active Expired - Lifetime
- 2004-02-02 CN CN2004800056355A patent/CN1756558B/en not_active Expired - Fee Related
- 2004-02-02 CA CA2514642A patent/CA2514642C/en not_active Expired - Fee Related
- 2004-02-02 PT PT110065042T patent/PT2441467E/en unknown
- 2004-02-02 DK DK04707422.4T patent/DK1589993T3/en active
- 2004-02-02 DK DK11006495.3T patent/DK2444102T3/en active
- 2004-02-02 ES ES10011598.9T patent/ES2541952T3/en not_active Expired - Lifetime
- 2004-02-02 JP JP2006503265A patent/JP5589165B2/en not_active Expired - Fee Related
- 2004-02-02 ES ES11006495.3T patent/ES2541785T3/en not_active Expired - Lifetime
- 2004-02-02 WO PCT/US2004/002973 patent/WO2004069190A2/en active Application Filing
- 2004-02-02 DK DK11006504.2T patent/DK2441467T3/en active
- 2004-02-02 MX MXPA05007822A patent/MXPA05007822A/en active IP Right Grant
- 2004-02-02 CN CN2012100330996A patent/CN102580066A/en active Pending
- 2004-02-02 EP EP04707422.4A patent/EP1589993B1/en not_active Expired - Lifetime
- 2004-02-02 HU HUE14197197A patent/HUE033381T2/en unknown
- 2004-02-02 SI SI200432261T patent/SI2441467T1/en unknown
- 2004-02-02 HU HUE11006504A patent/HUE027113T2/en unknown
- 2004-02-02 CA CA2814774A patent/CA2814774C/en not_active Expired - Fee Related
- 2004-02-02 BR BR0407001-1A patent/BRPI0407001A/en not_active Application Discontinuation
- 2004-02-02 CN CN2012100328939A patent/CN102586205A/en active Pending
- 2004-02-02 ES ES14197197.8T patent/ES2619353T3/en not_active Expired - Lifetime
- 2004-02-02 PT PT100115989T patent/PT2332567E/en unknown
- 2004-02-02 EP EP20110006495 patent/EP2444102B1/en not_active Expired - Lifetime
- 2004-02-02 CA CA2814767A patent/CA2814767C/en not_active Expired - Fee Related
- 2004-02-02 SI SI200432226T patent/SI1589993T1/en unknown
- 2004-02-02 ES ES16205400.1T patent/ES2686775T3/en not_active Expired - Lifetime
- 2004-02-02 PT PT110064953T patent/PT2444102E/en unknown
- 2004-02-02 DK DK14197197.8T patent/DK2857036T3/en active
- 2004-02-02 ES ES04707422.4T patent/ES2531478T3/en not_active Expired - Lifetime
- 2004-02-02 SI SI200432251T patent/SI2332567T1/en unknown
- 2004-02-02 ES ES11006504.2T patent/ES2545619T3/en not_active Expired - Lifetime
- 2004-02-02 DK DK10011598.9T patent/DK2332567T3/en active
- 2004-02-02 PT PT141971978T patent/PT2857036T/en unknown
-
2005
- 2005-07-06 IL IL169562A patent/IL169562A/en active IP Right Grant
- 2005-12-23 US US11/317,404 patent/US9597377B2/en not_active Expired - Fee Related
-
2006
- 2006-12-01 US US11/607,286 patent/US20070178081A1/en not_active Abandoned
-
2010
- 2010-10-20 JP JP2010235791A patent/JP2011078413A/en active Pending
-
2011
- 2011-08-03 IL IL214440A patent/IL214440A/en not_active IP Right Cessation
- 2011-08-03 IL IL214441A patent/IL214441A0/en unknown
- 2011-08-03 IL IL214439A patent/IL214439A0/en unknown
- 2011-12-14 HK HK11113493.2A patent/HK1158955A1/en not_active IP Right Cessation
-
2012
- 2012-01-04 JP JP2012000271A patent/JP5875870B2/en not_active Expired - Fee Related
- 2012-01-04 JP JP2012000270A patent/JP5808675B2/en not_active Expired - Fee Related
- 2012-09-27 HK HK12109528.8A patent/HK1168778A1/en not_active IP Right Cessation
- 2012-10-05 HK HK12109801.6A patent/HK1169033A1/en not_active IP Right Cessation
-
2015
- 2015-03-11 CY CY20151100242T patent/CY1116215T1/en unknown
- 2015-07-08 CY CY20151100594T patent/CY1116464T1/en unknown
- 2015-07-08 CY CY20151100593T patent/CY1116463T1/en unknown
- 2015-08-14 HK HK15107877.6A patent/HK1207291A1/en not_active IP Right Cessation
- 2015-08-26 CY CY20151100746T patent/CY1116747T1/en unknown
- 2015-09-08 IL IL241315A patent/IL241315A/en not_active IP Right Cessation
- 2015-11-10 JP JP2015220246A patent/JP6211573B2/en not_active Expired - Fee Related
-
2016
- 2016-12-05 IL IL249389A patent/IL249389A0/en unknown
-
2017
- 2017-03-20 CY CY20171100345T patent/CY1118849T1/en unknown
- 2017-08-14 US US15/675,968 patent/US20180085437A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344587B (en) | Combination therapy for treating protein deficiency disorders. | |
MXPA05007821A (en) | Combination therapy for treating protein deficiencies. | |
IL267381A (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
MX2007004551A (en) | Thiadiazole compounds and methods of use. | |
MY169308A (en) | Treatment of tnf? related disorders | |
MY172641A (en) | High concentration antibody and protein formulations | |
DE60331537D1 (en) | COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA | |
WO2005000215A3 (en) | Methods for treating pain | |
HK1085140A1 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
MXPA04000222A (en) | Combinations for the treatment of inflammatory disorders. | |
TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
SG169224A1 (en) | Method for treatment of tumors using nordihydrogualaretic acid derivatives | |
SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
EA200600921A1 (en) | METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES | |
BRPI0418157A (en) | allogeneic tumor therapy | |
MY135829A (en) | Analeptic and drug combinations | |
MY134288A (en) | Composition and its therapeutic use | |
MXPA06007007A (en) | Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours. | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |